“Natural history” clinical trials: An enduring contribution to modern medical practice

作者: Edward M. Scolnick , Eve E. Slater , George W. Williams

DOI: 10.1016/S0065-3233(01)56001-5

关键词:

摘要: Publisher Summary Although many examples of clinical investigation can be found throughout the history medicine, randomized controlled trial (RCT) emerged in mid-20th century as most powerful and scientifically sound way to establish efficacy safety medicines. Looking future, advent genomics coupled with advances information technology promises enhance power RCTs generate medical knowledge about both existing new therapies. Today, gold standard by which merits drug therapy must measured, provide major scientific support for contemporary practice medicine. In other words, statistical principles on trials are based aid treating physician making daily decisions oft uncertain management or prevention disease. For large pharmaceutical companies, several hundred a plethora compounds underway worldwide at any given time, involving thousands investigators more patients. The generated through should have great influence design allowing accurate identification eligible

参考文章(34)
Richard S. Rosenbloom, William J. Spencer, Engines of innovation : U.S. industrial research at the end of an era Harvard Business School Press. ,(1996)
Rekha Garg, Salim Yusuf, WD Bussmann, Peter Sleight, Andrew Uprichard, Barry Massie, Barry McGrath, Berit Nilsson, Bertram Pitt, Bruno Magnani, Carol Maskin, Ettore Ambrosioni, Ewa Rucinska, Franz X Kleber, Gary Jennings, Gianni Tognoni, Helmut Drexler, John GF Cleland, Joseph A Franciosa, Jouko Remes, Karl Swedberg, Kenneth Dickstein, Lothar Maass, Marc Pfeffer, Mark A Creager, Maryann Gordon, Michael Joy, Norman Sharpe, Pierre Desche, Robin McGarry, Rory Collins, Steven G Chrysant, Vincenzo Cicchetti, Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure JAMA: The Journal of the American Medical Association. ,vol. 273, pp. 1450- 1456 ,(1995) , 10.1001/JAMA.1995.03520420066040
Bruce M Psaty, Nicholas L Smith, David S Siscovick, Thomas D Koepsell, Noel S Weiss, Susan R Heckbert, Rozenn N Lemaitre, Edward H Wagner, Curt D Furberg, None, Health Outcomes Associated With Antihypertensive Therapies Used as First-Line AgentsA Systematic Review and Meta-analysis JAMA: The Journal of the American Medical Association. ,vol. 277, pp. 739- 745 ,(1997) , 10.1001/JAMA.1997.03540330061036
Eugene Passamani, Clinical Trials — Are They Ethical? New England Journal of Medicine. ,vol. 324, pp. 1589- 1592 ,(1991) , 10.1056/NEJM199105303242209
Terje R. Pedersen, John Kjekshus, Kåre Berg, Anders G. Olsson, Lars Wilhelmsen, Hans Wedel, Kalevi Pyörälä, Tatu Miettinen, Torben Haghfelt, Ole Færgeman, Gudmundur Thorgeirsson, Bengt Jönsson, J. Sanford Schwartz, Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation. ,vol. 93, pp. 1796- 1802 ,(1996) , 10.1161/01.CIR.93.10.1796
Kenneth F Schulz, Iain Chalmers, Richard J Hayes, Douglas G Altman, Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials JAMA: The Journal of the American Medical Association. ,vol. 273, pp. 408- 412 ,(1995) , 10.1001/JAMA.273.5.408
Wallace A. Marsh, Karen L. Rascati, Meta-analyses of the effectiveness of erythropoietin for end-stage renal disease and cancer. Clinical Therapeutics. ,vol. 21, pp. 1443- 1455 ,(1999) , 10.1016/S0149-2918(00)80003-X